In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

PCI in ACS patients with atrial fibrillation

Experts' Introduction

The management of patients with atrial fibrillation requiring PCI and is an evolving and fascinating topic, not only for those who are interested in antithrombotic therapy.

The duration of aspirin therapy, now limited to up to a maximum of 1 month in patients with prevailing thrombotic risk with a proposed default duration of one week; the selection of P2Y12 inhibitors (mostly clopidogrel); and the clear advantage of direct oral anticoagulant (OAC) over vitamin K antagonists in the vast majority of patients, are now emerging as preferred approaches in most patients but with the necessity of accurate quantification of the risk of both thrombosis and bleeding to personalize therapeutic decisions.

I hope this selection may help inform the treatment of your next patient.


leonardi-sergio-2018.jpgAssoc. Prof. Sergio Leonardi,  FESC

Pavia, Italy



Michael Spartalis - Greece.png

Resources below have been selected by Dr. Michael D. Spartalis

Young Member



ACVC Clinical Decision-Making Toolkit

acca-toolkit-2018-cover.jpgAccess the toolkit 






Acute Cardiovascular Care Congress Resources

ESC 365 visualA selection of resources from Acute Cardiovascular Care 2019:



Journal-Acute-Cardiovascular-Care-EHJ.pngImpact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry




ACVC Webinars on:



ESC Clinical Practice Guidelines